Emergent BioSolutions Inc. Common Stock (EBS)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — May 21, 2026Investment Snapshot
- Trading 64% below Graham Number ($22.45) — significant margin of safety
- Piotroski F-Score 7/9 — financially strong with improving fundamentals
- Strong ROE of 21.8% with 15.2% net margin
- Revenue declining 29% annually
Emergent BioSolutions Inc. Common Stock (EBS) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NYSE , with a market capitalisation of $421 million . Key value metrics: P/E ratio 3.7, P/B ratio 0.80, Piotroski F-Score 7 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Emergent BioSolutions Inc. Common Stock — Fundamental Analysis Summary
Emergent BioSolutions Inc. Common Stock (EBS) is trading 64% below its Graham Number of $22.45 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 3.7x.
On financial health, EBS shows a strong Piotroski F-Score of 7/9, indicating improving fundamentals across profitability, leverage, and efficiency, and strong return on equity of 21.8% (sector average: -20.6%), and elevated leverage with a debt-to-equity ratio of 1.13.
StockPik's composite Value Score for EBS is 100/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
EBS reports a solid gross margin of 58.2% (sector average: 40.1%) and a solid operating margin of 18.5%.
EBS shows revenue declining at 29% year-over-year, with earnings growing at 128%.